Hennion & Walsh Asset Management Inc. Has $1.09 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Hennion & Walsh Asset Management Inc. lifted its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 13.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 137,968 shares of the company’s stock after acquiring an additional 16,801 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.14% of Day One Biopharmaceuticals worth $1,094,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Handelsbanken Fonder AB lifted its holdings in Day One Biopharmaceuticals by 16.7% during the fourth quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $399,000 after purchasing an additional 4,500 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Day One Biopharmaceuticals by 43.4% in the fourth quarter. Bank of New York Mellon Corp now owns 244,829 shares of the company’s stock worth $3,102,000 after purchasing an additional 74,091 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Day One Biopharmaceuticals by 21.6% in the fourth quarter. Fisher Asset Management LLC now owns 89,132 shares of the company’s stock worth $1,129,000 after purchasing an additional 15,831 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Day One Biopharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 535,501 shares of the company’s stock worth $6,785,000 after purchasing an additional 28,053 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in Day One Biopharmaceuticals during the fourth quarter valued at approximately $143,000. 87.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on DAWN. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, May 7th. Needham & Company LLC lowered their price objective on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Finally, The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $30.57.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 13,964 shares of the stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the transaction, the chief executive officer now directly owns 145,737 shares in the company, valued at approximately $912,313.62. This represents a 8.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Charles N. York II sold 4,282 shares of the firm’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the completion of the sale, the chief financial officer now owns 265,231 shares of the company’s stock, valued at approximately $1,660,346.06. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,725 shares of company stock valued at $167,299 in the last three months. 6.20% of the stock is currently owned by corporate insiders.

Day One Biopharmaceuticals Trading Up 3.5%

DAWN opened at $7.19 on Friday. The company has a market cap of $728.79 million, a price-to-earnings ratio of -6.98 and a beta of -1.30. The company’s 50 day moving average is $6.94 and its 200 day moving average is $9.97. Day One Biopharmaceuticals, Inc. has a 12-month low of $6.08 and a 12-month high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The company had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. As a group, analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.